Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
This article was originally published in The Pink Sheet Daily
Company is pursuing priority review, eyes FDA-approval in mid-2012. If Quad is cleared, newly-approved Complera will take back seat.
You may also be interested in...
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.
Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.